Replimune Group, Inc. Stock News

WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company's Chief Commercial Officer.

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneer...

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an offering price of $12.06 per share and, in lieu of common stock to certain investors, pre-funded ...

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.

The U.S. Food and Drug Administration has approved ​Replimune's drug for a difficult-to-treat form ‌of skin cancer, the company said on Thursday, giving the biotech firm its first ​marketed product after years of regulatory ​setbacks.

The agency had turned down two earlier applications over clinical data-quality concerns.

Replimune stock soars after a FDA advisory committee votes that the company's study on its skin cancer treatment is ‘clinically meaningful.'

Shares ‌of Replimune more than doubled premarket on Friday after the U.S. Food and Drug Administration's panel of outside advisers voted to back trial results for its drug for a ​type of skin cancer.